Compare JRSH & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JRSH | RNXT |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1M | 36.4M |
| IPO Year | 2018 | 2021 |
| Metric | JRSH | RNXT |
|---|---|---|
| Price | $3.02 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $7.75 |
| AVG Volume (30 Days) | 88.4K | ★ 295.1K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | ★ 6.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $146,234,005.00 | $928,000.00 |
| Revenue This Year | $11.71 | $2,795.35 |
| Revenue Next Year | $7.69 | $272.69 |
| P/E Ratio | $61.26 | ★ N/A |
| Revenue Growth | ★ 12.25 | N/A |
| 52 Week Low | $2.81 | $0.70 |
| 52 Week High | $4.17 | $1.69 |
| Indicator | JRSH | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 51.11 |
| Support Level | $3.02 | $0.92 |
| Resistance Level | $3.15 | $0.93 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 20.45 | 76.75 |
Jerash Holdings (US) Inc along with its subsidiaries, is a manufacturer and exporter of customized, ready-made sport and outerwear from knitted fabric from its production facilities in Jordan. The company manufactures for retailers, including Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation, and Philip-Van Heusen, which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, Calvin Klein, Tommy Hilfiger, IZOD, and Speedo. It derives its revenue from the manufacturing and sales of outerwear in the United States. The company's product offering consists of jackets, polo shirts, crew neck shirts, pants, and shorts made from knitted fabric. Geographically, the company generates maximum revenue from the United States.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.